Evidence map›Paper›PMID 26423459›Full record

ArticleHuman molecular genetics2015

Use of the HPRT gene to study nuclease-induced DNA double-strand break repair.

Polly Gravells, Sara Ahrabi, Rajani K Vangala, Kazunori Tomita, James T Brash, Lena A Brustle, Christopher Chung, Julia M Hong, Aikaterini Kaloudi, Timothy C Humphrey and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Polly GravellsGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and.
Sara AhrabiCRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Rajani K VangalaGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and.
Kazunori TomitaGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and.
James T BrashGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and.
Lena A BrustleGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and.
Christopher ChungGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and.
Julia M HongGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and.
Aikaterini KaloudiGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and.
Timothy C HumphreyCRUK MRC Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Andrew C G PorterGene Targeting Group, Centre for Haematology, Imperial College Faculty of Medicine, London W120NN, UK and andy.porter@imperial.ac.uk.
Imperial College London · GBCRUK/MRC Oxford Institute for Radiation Oncology · GB

Funding

Biotechnology and Biological Sciences Research Council BB/H003371/1Cancer Research UK 12097Cancer Research UK C5255/A15935Medical Research Council MC_PC_12003
6 · The paper itself

Abstract

Understanding the mechanisms of chromosomal double-strand break repair (DSBR) provides insight into genome instability, oncogenesis and genome engineering, including disease gene correction. Research into DSBR exploits rare-cutting endonucleases to cleave exogenous reporter constructs integrated into the genome. Multiple reporter constructs have been developed to detect various DSBR pathways. Here, using a single endogenous reporter gene, the X-chromosomal disease gene encoding hypoxanthine phosphoribosyltransferase (HPRT), we monitor the relative utilization of three DSBR pathways following cleavage by I-SceI or CRISPR/Cas9 nucleases. For I-SceI, our estimated frequencies of accurate or mutagenic non-homologous end-joining and gene correction by homologous recombination are 4.1, 1.5 and 0.16%, respectively. Unexpectedly, I-SceI and Cas9 induced markedly different DSBR profiles. Also, using an I-SceI-sensitive HPRT minigene, we show that gene correction is more efficient when using long double-stranded DNA than single- or double-stranded oligonucleotides. Finally, using both endogenous HPRT and exogenous reporters, we validate novel cell cycle phase-specific I-SceI derivatives for investigating cell cycle variations in DSBR. The results obtained using these novel approaches provide new insights into template design for gene correction and the relationships between multiple DSBR pathways at a single endogenous disease gene.

Indexed as

DNA Breaks, Double-StrandedDNA RepairAnimalsBacterial ProteinsCell CycleCell Line, TumorCRISPR-Associated Protein 9CRISPR-Cas SystemsDeoxyribonucleases, Type II Site-SpecificEndonucleasesGenes, ReporterHeLa CellsHumansHypoxanthine PhosphoribosyltransferaseMiceMutagenesisBacterial ProteinsCas9 endonuclease Streptococcus pyogenesCRISPR-Associated Protein 9Deoxyribonucleases, Type II Site-SpecificEndonucleasesHypoxanthine PhosphoribosyltransferaseSaccharomyces cerevisiae ProteinsSCEI protein, S cerevisiae

Identifiers

PMID26423459
PMCPMC4654060
OpenAlexW2179684318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.